Alan Beggs, PhD, on Challenges in Therapeutic Development for Rare Diseases

Commentary
Video

The director of the Manton Center for Orphan Disease Research at Boston Children’s Hospital discussed takeaways from an MDA session on rare diseases.

“I think one of the hallmarks of this field is that we need to remain flexible. We need to see what the respond to potential essays and safety signals that may be dissipated, and then be ready to modify our approaches accordingly.”

There are many challenges to developing novel therapies for rare diseases which currently have no disease modifying therapies available for treatment. These include toxicities that may not be fully understood or expected, disease heterogeneity, clinical trial recruitment, and industry hesitance.

Alan Beggs, PhD, Sir Edwin & Lady Manton Professor of Pediatrics, and director, Manton Center for Orphan Disease Research, and core director, Molecular Genetics Core, Intellectual and Developmental Disabilities Research Center (IDDRC), Boston Children’s Hospital, chaired a session held at the 2024 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference, held March 3-6, in Orlando, Florida, that focused on developing gene therapy for rare and ultra-rare neuromuscular diseases, and namely focused on the AT132 gene therapy (Astellas Pharma) program for treating X-linked myotubular myopathy (MTM).

CGTLive spoke with Beggs to learn more about the session. He discussed some of these challenges and overviewed some challenges that the Astellas program faced. He shared some strategies that different groups are pursuing to overcome these challenges.

Click here to view more coverage of the 2024 MDA Conference.

REFERENCES
1. Beggs A, Buj-Bello A, Childers C, Dowling J, Gray J. Development of Gene Therapy for Rare and Ultra-Rare Neuromuscular Disease. Presented at: 2024 MDA Clinical and Scientific Conference; March 3-6; Orlando, FL.
2. Astellas reports update to September 1 announcement on the ASPIRO clinical trial of AT132 in patients with X-linked myotubular myopathy. News release. Astellas Pharma. September 14, 2021. https://www.prnewswire.com/news-releases/astellas-reports-update-to-september-1-announcement-on-the-aspiro-clinical-trial-of-at132-in-patients-with-x-linked-myotubular-myopathy-301375950.html
Related Videos
Nathan Yozwiak, PhD, on Researching AAV Gene Therapy Delivery to the Brain
Salvador Rico, MD, PhD, on Informing Clinical Trials With Natural History Studies in Dravet
Zheng-Yi Chen, DPhil, on International Collaboration on Clinical Trials
Janice Chen, PhD, the cofounder and chief technology officer of Mammoth Biosciences
Sekar Kethiresan, MD, on Following up VERVE-101 With Next-Generation Editing Therapies
Maria Escolar, MD, the chief medical officer of Forge Biologics
Leigh Ramos-Platt, MD, on Allowing Access and Ensuring Preparation for Gene Therapies
John Murphy, PhD, the chief scientific officer of Arbor Biotechnologies
Erika Fullwood Augustine, MD, MS, the associate chief science officer of the Kennedy Krieger Institute
Maria Escolar, MD, the chief medical officer of Forge Biologics
© 2024 MJH Life Sciences

All rights reserved.